Resultado de búsqueda
Hace 20 horas · Acquisition to expand Lilly's immunology pipeline with oral integrin therapies. INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Hace 20 horas · Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash (an aggregate of approximately $3.2 billion) payable at closing. The transaction has been approved by the boards of directors of both companies. The transaction is not subject to any financing condition and is expected ...
Hace 20 horas · 【ニューヨーク=吉田圭織】米製薬大手イーライ・リリーは8日、米バイオ医薬品のモーフィック・ホールディングを約32億ドル（約5100億円）で ...
Hace 20 horas · July 9, 2024 11:30 am. Eli Lilly and Company (LLY) is set to acquire Morphic Holding, Inc. (MORF), a biopharmaceutics outfit specialising in small-molecule integrin medicines, for approximately $3.2bn. Morphic’s shares soared by more than 75% after the news hit the wires on Monday 8 July 2024. Analysts have speculated that Eli Lilly’s ...
Hace 20 horas · He praised MORF-057 as a promising example of their integrin technology platform, aimed at enhancing treatment efficacy and tolerability in IBD. Under the terms of the agreement, Lilly will initiate a tender offer to acquire all outstanding shares of Morphic at $57 per share in cash, totaling approximately $3.2 billion.
Hace 20 horas · Kirkland & Ellis is representing Eli Lilly and Company (NYSE: LLY), which today announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biotechnology company that is developing oral integrin therapies for treatment of serious chronic diseases. Lilly plans to commence a tender offer to acquire all outstanding shares of Morphic for a […]
Hace 20 horas · MORF. -. On Tuesday, RBC Capital downgraded Morphic Therapeutic stock from Outperform to Sector Perform, setting a new price target of $57.00, down from the previous $70.00. This shift in rating ...
